Abstract:
Fertility management can include: administering to the subject one or more doses of a compound according to Formula I so as to reduce fertility in the subject. Fertility management can also include administering an effective amount of the compound to: impair Sertoli cell function in a male subject; inhibit spermatogenesis in the subject; reduce testis weight in the subject; reduce ovary weight in a female subject; reduce serum progesterone in the female subject; impair ovarian follicle function in the female subject; causing reversible fertility in the subject. In order to return fertility, the method can include ceasing administration of the compound to the subject so as to return fertility in the subject. The compound can be administered for irreversibly sterilizing the subject.
Abstract:
In one embodiment of a networking module, a first block receives a serial digital media signal, and provides a parallel digital media signal based on the serial digital media signal. A second block, operative with the first block, stores the parallel digital media signal in a corresponding slot in an outgoing frame, and sends the outgoing frame in response to receiving an incoming frame.
Abstract:
This invention relates to use of inhibitors of the transforming growth factor-β (TGF-β) type I receptor (ALK5) and/or the activin type I receptor (ALK4) in treating, preventing, or reducing fibrosis, cancer, and vascular injuries.
Abstract:
The invention provides a method for the separation and purification of two or three cellular components selected from genomic DNA, RNA and proteins from a single biological sample. The method comprises generating an aqueous solution containing the cellular components by lysing cells with a lysis solution; contacting the aqueous solution with an ion exchanger for genomic DNA and RNA to bind to the ion exchanger; collecting the flow-through which contains unbound proteins; eluting RNA from the ion exchanger; and eluting DNA from the ion exchanger. For the purification of any two of the cellular components, one of the components is not collected. The invention also provides reagent kits for carrying out the methods.
Abstract:
A method and apparatus for the collection of physiological data from a patient is disclosed herein. An electrode assembly comprises an external label identifying an anatomical location and an electrode identifying circuitry that produces a signal indicative of the anatomical location to which the electrode assembly is to be attached. The electrode assembly transmits both the collected physiological signal and the identification signal to a data monitor for collection and processing physiological data.
Abstract:
In one embodiment of a networking module, a first block receives a serial digital media signal, and provides a parallel digital media signal based on the serial digital media signal. A second block, operative with the first block, stores the parallel digital media signal in a corresponding slot in an outgoing frame, and sends the outgoing frame in response to receiving an incoming frame.
Abstract:
Provided is a novel two step chromatographic purification process (load and elute) for the isolation of genomic DNA. In this method the sample is loaded on the column and the genomic DNA product is eluted directly without any intermediate wash steps. This is accomplished by utilizing a restricted access resin (i.e., lid beads), which is easy to prepare and comprised of two layers with different properties with non-functional surfaces on the outer layer. The inner layer is modified with functional groups that act as ion-exchangers. Small molecules such as RNA and proteins can enter the inner part of the resin and larger genomic DNA molecules will pass through the resin. RNA and proteins are captured in the inner layer of the restricted access resin while genomic DNA is readily eluted in the flow-through.
Abstract:
Lonidamine derivatives can be useful in methods of treating, inhibiting, and/or preventing polycystic kidney disease (PKD). Accordingly, lonidamine derivatives can be administered in a therapeutically effective amount for inhibiting, and/or preventing polycystic kidney disease (PKD) in the subject. This can include administering a therapeutically effective amount of the lonidamine derivatives for inhibiting CFTR and/or Hsp90 or biological pathway thereof. Also, the method can include administering the lonidamine derivatives in a therapeutically effective amount for inhibiting ErbB2, Src, Raf-1, B-Raf, MEK, Cdk4, NKCC1, or combinations thereof. For example, the therapeutically effective amount of the lonidamine derivatives can be configured so as to provide a concentration in or adjacent to a kidney cell of about 0.25 uM or more or less.
Abstract:
An antenna system includes a reflector having a modified-paraboloid shape; and a multi-beam, multi-band feed array located at a focal point of the reflector so that the antenna system forms a multiple congruent beams that are contiguous. The system has a single reflector with non-frequency selective surface. The reflector is sized to produce a required beam size at K-band frequencies and is oversized at EHF-band frequencies. The synthesized reflector surface is moderately shaped and disproportionately broadens EHF-band and Ka-band beams compared to K-band beams. The synthesized reflector surface forms multiple beams each having a 0.5-degree diameter at K-band, Ka-band, and EHF band. The multi-beam, multi-band feed array includes a number of high-efficiency, multi-mode circular horns that operate in focused mode at K-band and defocused mode at Ka-band and EHF-band by employing “frequency-dependent” design for the horns.
Abstract:
Oligonucleotide tagged nucleoside triphosphates, OTNTPs, which are substrates for polymerases and or terminal nucleotidyl transferases are provided as well as methods of making these OTNTPs. Further provided are OTNTPs with fluorescent dyes including energy transfer dyes, attached to the oligonucleotide chain, OTNTPs with unnatural bases incorporated in the oligonucleotide sequence and methods for incorporating these OTNTPs in DNA or RNA. Also provided are methods for using the oligonucleotides on OTNTPs for amplifying the oligo sequence on the OTNTP using an amplification method described above. Further provided are reactive bifunctional amidites, methods of making these compounds and methods for detecting single nucleotide polymorphisms using the above OTNTPs. Methods for detecting differential gene expression using the OTNTPs and methods of separating specifically modified DNA or RNA using the OTNTPs are also provided.